News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
775,078 Results
Type
Article (54493)
Company Profile (337)
Press Release (720235)
Multimedia
Podcasts (126)
Webinars (23)
Section
Business (215708)
Career Advice (2882)
Deals (37146)
Drug Delivery (143)
Drug Development (86351)
Employer Resources (185)
FDA (17359)
Job Trends (15930)
News (366852)
Policy (35618)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2928)
Academic (1)
Accelerated approval (39)
Adcomms (33)
Allergies (163)
Alliances (52752)
ALS (189)
Alzheimer's disease (1796)
Antibody-drug conjugate (ADC) (362)
Approvals (17575)
Artificial intelligence (599)
Autoimmune disease (187)
Automation (46)
Bankruptcy (388)
Best Places to Work (12180)
BIOSECURE Act (22)
Biosimilars (205)
Biotechnology (218)
Bladder cancer (174)
Brain cancer (66)
Breast cancer (681)
Cancer (5239)
Cardiovascular disease (454)
Career advice (2439)
Career pathing (41)
CAR-T (305)
CDC (63)
Celiac Disease (2)
Cell therapy (820)
Cervical cancer (39)
Clinical research (73562)
Collaboration (1897)
Company closure (4)
Compensation (1216)
Complete response letters (76)
COVID-19 (2928)
CRISPR (107)
C-suite (961)
Cystic fibrosis (152)
Data (6629)
Decentralized trials (2)
Denatured (36)
Depression (157)
Diabetes (540)
Diagnostics (7122)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (286)
Drug pricing (218)
Drug shortages (31)
Duchenne muscular dystrophy (256)
Earnings (92386)
Editorial (68)
Employer branding (23)
Employer resources (163)
Events (124434)
Executive appointments (1061)
FDA (20661)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1591)
Gene editing (225)
Generative AI (51)
Gene therapy (680)
GLP-1 (1107)
Government (5176)
Grass and pollen (8)
Guidances (387)
Healthcare (20132)
HIV (73)
Huntington's disease (51)
IgA nephropathy (89)
Immunology and inflammation (297)
Immuno-oncology (75)
Indications (134)
Infectious disease (3234)
Inflammatory bowel disease (211)
Inflation Reduction Act (17)
Influenza (129)
Intellectual property (265)
Interviews (559)
IPO (17082)
IRA (59)
Job creations (4089)
Job search strategy (1983)
JPM (67)
Kidney cancer (20)
Labor market (88)
Layoffs (623)
Leadership (42)
Legal (8760)
Liver cancer (102)
Longevity (19)
Lung cancer (707)
Lymphoma (392)
Machine learning (47)
Management (63)
Manufacturing (871)
MASH (183)
Medical device (14427)
Medtech (14491)
Mergers & acquisitions (21166)
Metabolic disorders (1418)
mRNA (189)
Multiple sclerosis (178)
NASH (23)
Neurodegenerative disease (370)
Neuropsychiatric disorders (104)
Neuroscience (3179)
Neurotech (1)
NextGen: Class of 2026 (7132)
Non-profit (4929)
Now hiring (69)
Obesity (680)
Opinion (326)
Ovarian cancer (173)
Pain (227)
Pancreatic cancer (250)
Parkinson's disease (311)
Partnered (35)
Patents (536)
Patient recruitment (549)
Peanut (65)
People (63793)
Pharmaceutical (70)
Pharmacy benefit managers (32)
Phase 1 (22886)
Phase 2 (32244)
Phase 3 (24106)
Pipeline (6064)
Policy (342)
Postmarket research (2914)
Preclinical (9782)
Press Release (70)
Prostate cancer (267)
Psychedelics (59)
Radiopharmaceuticals (303)
Rare diseases (988)
Real estate (6447)
Recruiting (77)
Regulatory (26557)
Reports (54)
Research institute (2637)
Resumes & cover letters (456)
Rett syndrome (31)
RNA editing (20)
RSV (86)
Schizophrenia (163)
Series A (269)
Series B (201)
Service/supplier (15)
Sickle cell disease (109)
Special edition (26)
Spinal muscular atrophy (171)
Sponsored (45)
Startups (3923)
State (2)
Stomach cancer (21)
Supply chain (114)
Tariffs (96)
The Weekly (88)
Vaccines (1136)
Venture capital (99)
Weight loss (452)
Women's health (101)
Worklife (22)
Date
Today (150)
Last 7 days (901)
Last 30 days (3100)
Last 365 days (31375)
2026 (5477)
2025 (31541)
2024 (36634)
2023 (41549)
2022 (52767)
2021 (57460)
2020 (56293)
2019 (49536)
2018 (37486)
2017 (34299)
2016 (34174)
2015 (40235)
2014 (34166)
2013 (29547)
2012 (31643)
2011 (32177)
2010 (30394)
Location
Africa (931)
Alabama (89)
Alaska (7)
Arizona (328)
Arkansas (14)
Asia (43712)
Australia (7964)
California (11944)
Canada (3421)
China (1193)
Colorado (500)
Connecticut (509)
Delaware (353)
Europe (97479)
Florida (1775)
Georgia (384)
Hawaii (3)
Idaho (65)
Illinois (953)
India (76)
Indiana (551)
Iowa (23)
Japan (459)
Kansas (131)
Kentucky (45)
Louisiana (31)
Maine (72)
Maryland (1469)
Massachusetts (8598)
Michigan (349)
Minnesota (663)
Mississippi (7)
Missouri (142)
Montana (34)
Nebraska (29)
Nevada (130)
New Hampshire (86)
New Jersey (3162)
New Mexico (31)
New York (3144)
North Carolina (1601)
North Dakota (9)
Northern California (5858)
Ohio (357)
Oklahoma (21)
Oregon (45)
Pennsylvania (2399)
Puerto Rico (25)
Rhode Island (51)
South America (1304)
South Carolina (69)
South Dakota (1)
Southern California (4656)
Tennessee (191)
Texas (1845)
United States (42510)
Utah (360)
Vermont (1)
Virginia (284)
Washington D.C. (87)
Washington State (974)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
775,078 Results for "taconic biosciences formerly known as taconic farms inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Taconic Biosciences Acquires TransCure bioServices, Building a Comprehensive Global Platform for Humanized Mouse Translational Research
January 21, 2026
·
4 min read
Press Releases
Taconic and Cyagen Collaborate to Streamline Access to Preclinical Mouse and Rat Models
August 5, 2025
·
3 min read
Press Releases
Taconic Biosciences Enters Into an Exclusive License Agreement With Helmholtz Munich to Expand Its CRISPR/Cas9 Gene Editing Services
June 9, 2025
·
2 min read
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
In this episode presented by Taconic Biosciences, BioSpace’s head of insights Lori Ellis discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment with Mike Garrett, CEO.
September 4, 2025
·
1 min read
·
Lori Ellis
Press Releases
Taconic Biosciences Announces New U.S. West Coast Production Location
November 21, 2024
·
2 min read
Deals
H.I.G. Capital Completes Sale of Taconic Biosciences
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (“Taconic” or the “Company”) to Avista Capital Partners (“Avista”).
November 1, 2022
·
4 min read
Press Releases
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
February 26, 2026
·
7 min read
Deals
Avista Capital Partners Acquires Taconic Biosciences
Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.
November 1, 2022
·
3 min read
Press Releases
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
January 26, 2026
·
5 min read
Pharm Country
Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment
Taconic Biosciences has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors known to confound results in antibody-based therapy studies.
October 24, 2022
·
2 min read
1 of 77,508
Next
